The information contained in the Organizational Database (ODB) is provided for informational purposes only. There is no implied endorsement by NORD. NORD does not promote or endorse participation in any specific organization. The information is subject to change without notice. Every effort is made to ensure that the details for each entry are as current as possible.
26 Cadogan Square
London, SW1X 0JP United Kingdom
+44 (0)20 7193 8921
The Myrovlytis Trust is a UK based, non-profit charity that promotes research into rare genetic disorders, and advances education of the public in medical and molecular genetics. The Trust funds basic scientific and medical research into Birt-Hogg-Dubé (BHD) syndrome. Several projects are currently being funded in university laboratories around the world, including projects ranging from cell biology to renal gene therapy. The Trust has also created and maintains www.BHDSyndrome.org (in collaboration with the BHD Family Alliance), the primary online resource for anyone interested in BHD syndrome. BHD syndrome is a rare complex genetic skin disorder (genodermatosis) characterized by the development of benign skin tumors (hamartomas) affecting the head, face and upper torso. These benign tumors are fibrofolliculomas, tumors of the hair follicles. BHD syndrome also predisposed individuals to the development of benign cysts in the lungs, repeated episodes of a collapsed lung (pneumothorax), and increased risk for developing renal neoplasia. BHD syndrome is caused by mutations in the BHD gene and is inherited as an autosomal dominant trait.
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.
NORD's Rare Disease Information Database is copyrighted and may not be published without the written consent of NORD.